|
|
Volumn 99, Issue 23, 2007, Pages 1750-1752
|
|
In Australia, patients and government at odds over mesothelioma treatment costs.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC ANTIMETABOLITE;
ASBESTOS;
CARCINOGEN;
CISPLATIN;
DRUG DERIVATIVE;
GLUTAMIC ACID DERIVATIVE;
GUANINE;
PEMETREXED;
QUINAZOLINE DERIVATIVE;
RALTITREXED;
THIOPHENE DERIVATIVE;
ABDOMINAL TUMOR;
AUSTRALIA;
CANADA;
COST BENEFIT ANALYSIS;
ECONOMICS;
ENVIRONMENTAL EXPOSURE;
GOVERNMENT;
HEALTH CARE COST;
HUMAN;
INCIDENCE;
LUNG TUMOR;
MESOTHELIOMA;
NOTE;
PATIENT ADVOCACY;
POLITICS;
THORAX TUMOR;
UNITED KINGDOM;
ABDOMINAL NEOPLASMS;
ANTIMETABOLITES, ANTINEOPLASTIC;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
ASBESTOS;
AUSTRALIA;
CANADA;
CARCINOGENS;
CISPLATIN;
COST-BENEFIT ANALYSIS;
ENVIRONMENTAL EXPOSURE;
GLUTAMATES;
GOVERNMENT;
GREAT BRITAIN;
GUANINE;
HEALTH CARE COSTS;
HUMANS;
INCIDENCE;
LOBBYING;
LUNG NEOPLASMS;
MESOTHELIOMA;
PATIENT ADVOCACY;
QUINAZOLINES;
THIOPHENES;
THORACIC NEOPLASMS;
|
|
EID: 38449114428
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djm257 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
